Get the Stockscreener App
1.33
5.67%
-0.08
Pre-market:
1.34
0.01
+0.75%
Nautilus Biotechnology Inc stock is traded at $1.33, with a volume of 198.74K.
It is down -5.67% in the last 24 hours and up +57.42% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$1.41
Open:
$1.41
24h Volume:
198.74K
Relative Volume:
0.49
Market Cap:
$167.99M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-2.375
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
+9.02%
1M Performance:
+57.42%
6M Performance:
+93.15%
1Y Performance:
-48.85%
1-Day Range:
$1.28
$1.4532
1-Week Range:
$1.21
$1.6301
52-Week Range:
$0.62
$2.9181
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
1.33 | 178.09M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Is this a good reentry point in Nautilus Biotechnology Inc.July 2025 Big Picture & Expert Curated Trade Setup Alerts - newser.com
How Nautilus Biotechnology Inc. stock performs in rate cut cyclesJuly 2025 Patterns & Daily Technical Stock Forecast Reports - newser.com
Can Nautilus Biotechnology Inc. stock weather global recessionJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Identifying reversal signals in Nautilus Biotechnology Inc.Forecast Cut & Weekly Setup with ROI Potential - newser.com
Is Nautilus Biotechnology Inc. stock oversold or undervaluedForecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
What candlestick patterns are forming on Nautilus Biotechnology Inc.July 2025 Technicals & Stepwise Entry/Exit Trade Alerts - newser.com
Has Nautilus Biotechnology Inc. found a price floorJuly 2025 Technicals & Accurate Intraday Trading Signals - newser.com
Will Nautilus Biotechnology Inc. stock outperform value stocks2025 Top Decliners & AI Driven Price Predictions - newser.com
Why Nautilus Biotechnology Inc. stock is recommended by analysts2025 Price Targets & Real-Time Price Movement Reports - newser.com
How Nautilus Biotechnology Inc. stock reacts to oil pricesPortfolio Risk Report & Reliable Entry Point Trade Alerts - newser.com
Nautilus Biotechnology (NASDAQ:NAUT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
How geopolitical tensions affect Nautilus Biotechnology Inc. stock2025 Winners & Losers & Growth Focused Stock Pick Reports - newser.com
Published on: 2025-11-01 11:48:31 - newser.com
Why Nautilus Biotechnology Inc. stock is considered a top pickQuarterly Earnings Summary & Weekly Momentum Stock Picks - newser.com
Strategies to average down on Nautilus Biotechnology Inc.July 2025 Drop Watch & Real-Time Volume Analysis - newser.com
How to recover losses in Nautilus Biotechnology Inc. stock2025 Top Decliners & Community Consensus Trade Signals - newser.com
Long term hold vs stop loss in Nautilus Biotechnology Inc.Market Activity Report & Real-Time Chart Breakout Alerts - newser.com
Earnings visualization tools for Nautilus Biotechnology Inc.July 2025 Outlook & Free Safe Capital Growth Stock Tips - newser.com
Nautilus Biotech Earnings Call Highlights Strategic Progress - TipRanks
Nautilus Biotechnology Inc (NAUT) Q3 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Nautilus Biotechnology Faces Nasdaq Delisting Risk Amid Compliance Challenges - TipRanks
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2025 Earnings Call Transcript - Insider Monkey
Nautilus anticipates early access Tau assay launch in H1 2026 while strengthening proteoform platform partnerships - MSN
Nautilus Biotechnology Advances Toward 2026 Commercial Launch - TipRanks
Nautilus Biotechnology And 2 Other Promising Penny Stocks - Yahoo Finance
Nautilus Biotechnology Narrows Losses And Gains Analyst Confidence - Finimize
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):